Treatment
Induction therapy clinical trials
We’re tracking 80 recruiting studies that include Induction therapy, each written for real people, not researchers, below.
Recruiting studies
- NCT04702256RecruitingPhase 3
Treating lupus kidney inflammation with or without extra steroid tablets
This trial tests whether adding standard oral steroid tablets to mycophenolate helps lupus nephritis (inflammation of the kidneys) more than using obinutuzumab plus mycophenolate, without extra oral steroids. It may help find a treatment plan that controls active kidney disease while changing how much steroid is used.
ParisAges 14 years+ - NCT05401097RecruitingPhase 2
Venetoclax plus IDH-targeted pills for AML patients who can’t get intensive chemo
This Phase 2 trial tests different ways of using medicines that target IDH mutations (IDH-targeted treatment) plus venetoclax in people newly diagnosed with IDH-mutated AML. It’s designed for patients who cannot safely receive intensive induction chemotherapy, to see which approach works best and is tolerable.
Aurora, ColoradoAges 18 years+ - NCT05639972RecruitingPhase 1/Phase 2
HPV cancer trial using immune T cells made for you
This Phase 1/2 trial tests a one-time infusion of special immune T cells made to recognize your HPV16 tumor. It may help your body attack the cancer, while researchers closely monitor safety and early effectiveness.
New Brunswick, New JerseyAges 18 years+ - NCT05766800RecruitingPhase 2
PD-1 plus chemotherapy before surgery for advanced lung cancer
This trial studies whether giving a PD-1 antibody together with standard chemotherapy before surgery can improve outcomes for people with stage IIIB–IIIC non-small cell lung cancer. It aims to shrink or control the cancer and make treatment before surgery more effective.
ShanghaiAges 18 years+ - NCT05936086Recruiting
Testing high-dose cyclophosphamide to treat adult HLH
This trial studies whether giving high-dose cyclophosphamide as an initial treatment works better for adults with HLH. HLH is a serious, overactive immune condition, and the study aims to improve control of the illness and safety.
ChongqingAges 18–65 - NCT06221683RecruitingPhase 2
Personalized induction therapy for children with AML based on genetics
This trial tests different induction therapy options based on the specific genetic subtype of a child’s AML and how the leukemia responds early on. The goal is to personalize treatment to improve outcomes and reduce side effects.
Hefei, AnhuiAges Up to 18 years - NCT06409702RecruitingPhase 4
Treating high-risk multiple myeloma with MRD testing
This trial tests a treatment plan for people with newly diagnosed high-risk multiple myeloma. It uses a special test called minimal residual disease (MRD) detection to see how well the treatment is working and guide next steps.
Suzhou, JiangsuAges 18 years+ - NCT06451861RecruitingPhase 2
Testing a new drug combo for newly diagnosed AML
This trial tests a new combination of drugs (ABC-14) against the standard treatment for adults newly diagnosed with acute myeloid leukemia (AML) who haven't had intensive treatment yet. The goal is to see if the new combo works better and is safe.
Dongguan, GuangdongAges 18 years+ - NCT06463717Recruiting
Stem cell transplant timing for multiple myeloma with no cancer cells left
This trial looks at people with newly diagnosed multiple myeloma who have no detectable cancer cells after initial treatment. It aims to see if these patients can do well without a stem cell transplant or with a delayed one, reducing unnecessary side effects.
Hangzhou, ZhejiangAges 18–70 - NCT06496659Recruiting
Lung segmentectomy after chemo or immunotherapy
This study tests a type of lung surgery called segmentectomy for people whose lung cancer shrank after chemotherapy or immunotherapy. The goal is to see if removing just the tumor part is safe and effective.
Chicago, IllinoisAges 18–89 - NCT06664411RecruitingPhase 2
Pola-ZR2P for untreated DLBCL
This trial tests a new combination of drugs (Pola-ZR2P) for people with a type of lymphoma called diffuse large B-cell lymphoma (DLBCL) who have not had chemotherapy yet. It aims to see if this treatment is safe and effective.
Beijing, Beijing MunicipalityAges 14 years+ - NCT06891144Recruiting
Study of older adults with AML getting intensive treatment
This study follows people aged 60 and older with newly diagnosed acute myeloid leukemia (AML) who are receiving strong chemotherapy. It aims to learn more about their health outcomes and better understand the disease in this age group.
AngersAges 60 years+ - NCT07044687RecruitingPhase 4
Venetoclax with azacitidine for newly diagnosed AML
This trial tests a combination of oral venetoclax and injected azacitidine for adults who are newly diagnosed with acute myeloid leukemia (AML) and cannot have standard strong chemotherapy. The goal is to see how well this treatment works and what side effects it may cause.
Gurgaon, HaryanaAges 18 years+ - NCT07149857RecruitingPhase 2
A study of CAR-T therapy for newly diagnosed multiple myeloma
This trial tests a one-time cell therapy called ciltacabtagene autoleucel (a CAR-T treatment) in people who have newly diagnosed multiple myeloma and are not eligible for a stem cell transplant. It aims to see if this treatment is safe and effective as an early therapy.
San Francisco, CaliforniaAges 18–80 - NCT07313462Recruiting
Comparing treatment strategies for MS starting after age 50
This trial looks at two ways to treat multiple sclerosis (MS) that begins after age 50. It compares starting with a stronger medication right away versus starting with a milder one and then switching if needed.
StrasbourgAges 50 years+ - NCT07340463RecruitingPhase 2
Biologics vs standard therapy for lupus kidney disease
This trial tests two biologic drugs (belimumab or telitacicept) compared to a standard treatment (mycophenolate mofetil) for people with active lupus nephritis. The goal is to see if biologics work better at controlling kidney inflammation over 6 months.
Nanjing, JiangsuAges 14–65 - NCT06092957RecruitingPhase 3
Reduced radiation after chemo-immunotherapy for high-risk nasopharyngeal cancer
This trial tests whether a lower dose of radiation, with or without additional chemo-immunotherapy, works as well as the standard full-dose chemoradiation for people with advanced nasopharyngeal cancer who had a complete response after initial chemo-immunotherapy.
Guangzhou, GuangdongAges 18–70 - NCT06846450RecruitingPhase 3
Comparing radiation types for nasopharyngeal cancer
This trial compares two types of radiation therapy (IMRT or IMPT plus CIRT) to see which works better for patients with nasopharyngeal cancer that hasn't spread. It's for people who have not had radiation to the head or neck before.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05422690RecruitingPhase 2
Treating bile duct cancer with chemo plus Y-90 radiation
This Phase 2 study tests whether combining chemotherapy (gemcitabine and cisplatin) and an immunotherapy drug (durvalumab) with targeted Y-90 radiation can shrink inoperable intrahepatic cholangiocarcinoma tumors. It’s looking for better tumor shrinking and improved cancer control.
Fairfax, VirginiaAges 18 years+ - NCT06912074RecruitingPhase 2
Comparing shorter vs. longer radiation after chemo-immunotherapy for esophageal cancer
This trial tests if a shorter course of radiation is as effective as the standard longer course after initial chemotherapy plus immunotherapy in people with advanced esophageal cancer that cannot be surgically removed.
Guangzhou, GuangdongAges 18–80 - NCT07159880Recruiting
Letrozole for ovulation induction in PCOS
This trial tests a longer course of letrozole to help women with PCOS ovulate and get pregnant. The goal is to see if extended therapy works better than the standard treatment.
São Paulo, São PauloAges 18–40 - NCT07298421RecruitingPhase 3
Testing afimkibart for children with Crohn's disease
This trial tests a medicine called afimkibart for children with moderately to severely active Crohn's disease. It aims to see how well the drug works and how safe it is when used for both starting and ongoing treatment.
New York, New YorkAges 2–17 - NCT07223814RecruitingPhase 3
Testing a new drug with standard chemo for AML
This trial adds an experimental drug called bleximenib to the usual chemotherapy for people newly diagnosed with AML who have certain genetic changes (NPM1 or KMT2A). The goal is to see if adding this drug helps the treatment work better.
San Francisco, CaliforniaAges 18 years+ - NCT06819878RecruitingPhase 3
Afimkibart for moderate to severe Crohn's disease
This study tests an experimental drug called afimkibart for people with moderate to severe Crohn's disease who haven't responded well to other treatments. The goal is to see if the drug can help control symptoms and reduce inflammation over time.
Dothan, AlabamaAges 16–80
Common questions
- Are there clinical trials studying Induction therapy?
- Yes. Clin2 currently lists 80 recruiting studies that include Induction therapy, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Induction therapy trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Induction therapy an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Induction therapy or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.